On the 27th of last month (local time) at the Yangon General Hospital in Yangon, the old capital of Myanmar, medical staff are preparing for the vaccination of Coby Shield, a novel coronavirus infection (Corona 19) vaccine from AstraZeneca and Oxford University. Yangon = EPA Yonhap News
The World Health Organization (WHO) approved the emergency use of a novel coronavirus infection (Corona 19) vaccine developed by a multinational pharmaceutical company AstraZeneca and Oxford University in the UK on the 15th (local time).
At a press briefing, WHO Secretary General Thewardros Adhanom Governor Yeosus announced that SK Bioscience of Korea and Serum Institute of India (SII) have put the AstraZeneca vaccine on the list of emergency use.
WHO emergency use approval is a prerequisite to supplying vaccines through COVAX facilities (co-purchase and distribution of international vaccines). With this approval, AstraZeneca vaccine can be distributed worldwide through COVAX. Accordingly, regulatory authorities in each country can quickly approve the import and vaccination of the AstraZeneca vaccine.
SK Bioscience Plant in Andong, Gyeongbuk, where the AstraZeneca vaccine is on commission yunhap news
“The two companies are producing the same vaccine, but they are making it at different factories, so separate reviews and approvals were needed,” said Governor Yeosus, who approved each of the two versions of the AstraZeneca vaccine.
He added, “The (approval) was completed within just 4 weeks of receiving the documents from the manufacturer,” he said. “WHO’s urgent use list evaluates and guarantees the quality, safety and efficacy of the Corona 19 vaccine.”
The WHO Immunization Strategy Advisory Group (SAGE) previously evaluated that the AstraZeneca vaccine was effective at 63.09% on the 10th, and recommended that adults 18 years of age or older can use it without age restrictions.
WHO previously approved the emergency use of the Corona 19 vaccine made by Pfizer and Bioentech on December 31 last year.
“We need to increase the production of (vaccines), and we continue to urge vaccine developers to submit documents to high-income countries as well as to the WHO,” said Governor Yeosus.
Ryuho reporter [email protected]
News directly edited by the Hankook Ilbo can also be viewed on Naver.
